Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For stem cell donors:
- Donors must be aged 18 or older
- Donors must provide signed consent to take part
For transplant recipients:
- Recipients must be aged 18 or older
- Recipients must provide signed consent and be willing to be followed up for one year after their transplant
- Recipients must have a reasonably good level of physical functioning (confirm with trial site)
- Recipients must be scheduled to receive a stem cell transplant to treat one of these blood cancers: Hodgkin or Non-Hodgkin lymphoma, myelodysplastic syndrome, acute lymphoblastic leukemia in first or second remission, acute myeloid leukemia in first or second remission, chronic myelogenous leukemia at certain stages, chronic lymphocytic leukemia, myeloproliferative disorders, or myelofibrosis
- Recipients must have tested positive for a previous exposure to the CMV virus (cytomegalovirus)
- Recipients must be receiving a transplant from a related donor with a full 8 out of 8 tissue-type match
- Recipients must have liver function test results within an acceptable range (confirm with trial site)
- Recipients must have kidney function within an acceptable range (confirm with trial site)
- Recipients must have adequate heart function, with the heart pumping at 50% or above, tested within 45 days before starting the trial
- Recipients must have adequate lung function, tested within 45 days before starting the trial
- Recipients must test negative for HIV, hepatitis B, hepatitis C, and syphilis (people with an undetectable viral load may still be eligible — confirm with trial site)
- Recipients must meet all other infection screening requirements, tested within 45 days before starting the trial
- Female recipients who could become pregnant must have a negative pregnancy test before joining
- Female and male recipients who could become pregnant or cause a pregnancy must agree to use effective contraception or abstain from heterosexual activity from before the trial starts until at least 90 days after the transplant
Who may not be able to join:
For stem cell donors:
- Donors who have previously had any type of transplant
- Donors who have received chemotherapy, radiation, biological therapy, or immunotherapy within the past 21 days
- Donors who have received any vaccine (standard or experimental) within the past 30 days, or who are planned to receive one within 30 days after the study vaccine
- Donors who are not medically fit for the standard stem cell collection process — for example, due to abnormal blood counts, history of stroke, or uncontrolled high blood pressure
- Donors who have a sickle cell-related blood condition
- Donors with certain heart function abnormalities detected on testing
- Donors who test positive for HIV, active hepatitis B or C, or HTLV-I/II
- Donors with severe psychiatric illness or a condition that would make it impossible to give informed consent or follow the donation process
- Female donors who are pregnant or breastfeeding
- Donors with any other condition that the investigator believes would make participation unsafe or not feasible
For transplant recipients:
- Recipients who have previously received any experimental CMV vaccine
- Recipients who have received experimental anti-CMV drug treatment in the past 6 months
- Recipients who have previously had an allogeneic (donor) stem cell transplant for any condition
- Recipients who have recently received a live vaccine
- Recipients who are currently receiving certain other vaccines or allergy injection treatments (confirm with trial site)
- Recipients who are receiving a medication called alemtuzumab or similar drugs that deplete T-cells
- Recipients who are taking antiviral medications used specifically to treat CMV, such as valganciclovir, ganciclovir, foscarnet, cidofovir, brincidofovir, or maribavir (acyclovir for herpes simplex is permitted)
- Recipients receiving preventive CMV antibody treatment or preventive antiviral CMV therapy
- Recipients currently enrolled in another clinical trial involving experimental drugs with unknown effects on CMV or unknown safety profiles
- Recipients taking other medications that could interfere with assessing how the trial treatment works
- Recipients who have been diagnosed with an autoimmune disease
- Female recipients who are pregnant or breastfeeding
- Recipients with multiple myeloma
- Recipients with any other condition that the investigator believes would make participation unsafe or not feasible
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Vaibhav Agrawal, MD, City of Hope Medical Center
Phone: 626-359-8111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time from transplantation to cytomegalovirus (CMV) disease or pre-emptive treatment following CMV reactivation (efficacy); Occurrence of non-relapse mortality (safety in HCT-recipients); Incidence of severe acute graft versus host disease (aGHVD) (safety in HCT-recipients); Incidence of severe adverse events (AEs) (safety in HCT-recipients); Incidence of grade 3 and higher AEs (safety in HCT-donors)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.